| Entry |
|
|---|
| Name |
Adalimumab (USAN/INN);
Adalimumab (genetical recombination) (JAN);
Adalimumab (genetical recombination) [Adalimumab biosimilar 1] (JAN);
Adalimumab (genetical recombination) [Adalimumab biosimilar 2] (JAN);
Adalimumab (genetical recombination) [Adalimumab biosimilar 3] (JAN);
Adalimumab-adaz;
Adalimumab-adbm;
Adalimumab-afzb;
Adalimumab-atto;
Adalimumab-bwwd;
Adalimumab-fkjp;
Humira (TN);
Abrilada (TN);
Amjevita (TN);
Cyltezo (TN);
Hadlima (TN);
Hyrimoz (TN) |
|---|
| Product |
HUMIRA (A-S Medication Solutions), HUMIRA (AbbVie) |
|---|
| Class |
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG01936 TNF inhibitor
|
|---|
| Remark |
| Therapeutic category: | 3999 |
|
|---|
| Efficacy |
Anti-inflammatory, Antirheumatic, Anti-TNF-alpha antibody |
|---|
| Disease |
Rheumatoid arthritis [DS:H00630]
Juvenile idiopathic arthritis [DS:H01672]
Psoriatic arthritis [DS:H01507]
Ankylosing spondylitis [DS:H01674]
Adult Crohn's disease [DS:H00286]
Pediatric Crohn's disease [DS:H00286]
Ulcerative colitis [DS:H01466]
Plaque psoriasis [DS:H01656]
Hidradenitis suppurativa [DS:H00681] |
|---|
| Comment |
Monoclonal antibody
|
|---|
| Target |
TNF (TNFA, TNFSF2) [HSA:7124] [KO:K03156] |
|---|
| Pathway |
| hsa04010 | MAPK signaling pathway |
| hsa04060 | Cytokine-cytokine receptor interaction |
| hsa04350 | TGF-beta signaling pathway |
| hsa04380 | Osteoclast differentiation |
| hsa04612 | Antigen processing and presentation |
| hsa04650 | Natural killer cell mediated cytotoxicity |
| hsa05321 | Inflammatory bowel disease |
| hsa05323 | Rheumatoid arthritis |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07050 | Antirheumatics - DMARDs and biological agents |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors
L04AB04 Adalimumab
D02597 Adalimumab (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunosuppressants
Tumor Necrosis Factor (TNF) Blockers
Adalimumab
D02597 Adalimumab (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D02597 Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN); Adalimumab (genetical recombination) [Adalimumab biosimilar 1] (JAN); Adalimumab (genetical recombination) [Adalimumab biosimilar 2] (JAN); Adalimumab (genetical recombination) [Adalimumab biosimilar 3] (JAN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG01936 TNF inhibitor
D02597 Adalimumab
Drug classes [BR:br08332]
Immunological agent
DG01936 TNF inhibitor
D02597 Adalimumab
Antirheumatic agent
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D02597 Adalimumab
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokines
Tumor necrosis factors
TNF (TNFA, TNFSF2)
D02597 Adalimumab (USAN/INN) <JP/US>
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D02597
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D02597
|
|---|
| Other DBs |
|
|---|